Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and augmented intelligence to identify the source of chronic low back pain, has added Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. This Beverly Hills-based private practice is recognized for its expertise in complex spinal procedures and high surgical volume. The inclusion represents the first private practice site in the trial, reflecting growing interest in integrating Aclarion's Nociscan platform into real-world clinical workflows beyond academic medical centers.
The CLARITY trial—Chronic Low bAck pain Randomized Independent Trial studY—is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS scale at 12 months compared to baseline, with several secondary endpoints. The company anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery and a neurosurgeon with over 25 years of experience, emphasized the importance of precise diagnostics. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique,” he said. “Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
Ryan Bond, Chief Strategy Officer of Aclarion, noted the strategic importance of private practice involvement. “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice,” he said. Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care.
Chronic low back pain affects approximately 266 million people worldwide, making it a global healthcare challenge. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain using magnetic resonance spectroscopy (MRS) data from an MRI machine. When all Nociscan-positive discs are treated, the technology demonstrates a 97% surgical success rate. The CLARITY trial aims to generate high-quality evidence to further validate these outcomes and advance the platform's adoption.
For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
